RedHill Biopharma (NASDAQ:RDHL) has dosed the first patient with COVID-19 infection with its IND, opaganib (Yeliva, ABC294640), in Israel.
The treatment is administered under a
compassionate use program in accordance with the Israeli Ministry of
Health guidelines, with additional patients expected to be treated in
coming days.
RedHill is also preparing for potential ramp-up of manufacturing of opaganib.
Shares are up 9% premarket.
https://seekingalpha.com/news/3558482-redhill-bio-doses-first-covidminus-19-patient-opaganib-in-israel-shares-up-9-premarket
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.